Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Atea Pharmaceuticals (AVIR) EPS (Basic) (2020 - 2022)

Atea Pharmaceuticals (AVIR) has 3 years of EPS (Basic) data on record, last reported at -$0.4 in Q4 2022.

  • For Q4 2022, EPS (Basic) fell 128.37% year-over-year to -$0.4; the TTM value through Dec 2022 reached -$1.39, down 195.21%, while the annual FY2025 figure was -$1.94, 3.0% up from the prior year.
  • EPS (Basic) reached -$0.4 in Q4 2022 per AVIR's latest filing, down from -$0.1 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $2.62 in Q4 2020 and bottomed at -$1.74 in Q3 2020.
  • Average EPS (Basic) over 3 years is -$0.04, with a median of -$0.36 recorded in 2021.
  • Peak YoY movement for EPS (Basic): skyrocketed 192.5% in 2021, then crashed 2000.0% in 2022.
  • A 3-year view of EPS (Basic) shows it stood at $2.62 in 2020, then tumbled by 46.18% to $1.41 in 2021, then plummeted by 128.37% to -$0.4 in 2022.
  • Per Business Quant database, its latest 3 readings for EPS (Basic) were -$0.4 in Q4 2022, -$0.1 in Q3 2022, and -$0.38 in Q2 2022.